Trial Profile

A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced or Metastatic Her-2-Positive Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 754807 (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Biomarker; Pharmacogenomic

Most Recent Events

12 Jul 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
04 Mar 2012 EudraCT reports actual initiation date as Apr 2010; additional trial centre identified and inclusion, exclusion criteria amended.
03 Mar 2012 Planned End Date changed from 1 Mar 2012 to 1 Apr 2013 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com